474 related articles for article (PubMed ID: 32435020)
1. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
[TBL] [Abstract][Full Text] [Related]
3. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
4. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
[TBL] [Abstract][Full Text] [Related]
5. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl M
Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
[TBL] [Abstract][Full Text] [Related]
7. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
[TBL] [Abstract][Full Text] [Related]
9. Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy.
Lumry W; Templeton T; Omert L; Levy D
J Infus Nurs; 2020; 43(3):134-145. PubMed ID: 32287168
[TBL] [Abstract][Full Text] [Related]
10. Nanofiltered human C1 inhibitor concentrate (Cinryze®): in hereditary angioedema.
Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):317-27. PubMed ID: 21942916
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study.
Martinez-Saguer I; Cicardi M; Suffritti C; Rusicke E; Aygören-Pürsün E; Stoll H; Rossmanith T; Feussner A; Kalina U; Kreuz W
Transfusion; 2014 Jun; 54(6):1552-61. PubMed ID: 24266596
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W; Hébert J; Hanzlikova J; Staubach-Renz P; Martinez-Saguer I; Magerl M; Aygören-Pürsün E; Farkas H; Reshef A; Kivity S; Neri S; Crisan I; Caballero T; Baeza ML; Hernandez MD; Li H; Lumry W; Bernstein JA; Hussain I; Anderson J; Schwartz LB; Jacobs J; Manning M; Levy D; Riedl M; Christiansen S; Feuersenger H; Pragst I; Mycroft S; Pawaskar D; Jacobs I;
J Allergy Clin Immunol Pract; 2019; 7(6):1793-1802.e2. PubMed ID: 30772477
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.
Johnson F; Stenzl A; Hofauer B; Heppt H; Ebert EV; Wollenberg B; Lochbaum R; Hahn J; Greve J; Trainotti S
Clin Rev Allergy Immunol; 2023 Dec; 65(3):354-364. PubMed ID: 37914894
[TBL] [Abstract][Full Text] [Related]
14. C1-esterase inhibitor (Cinryze
Gupta R; Balduzzi J; Davis-Lorton M
Immunotherapy; 2018 Jun; 10(8):635-642. PubMed ID: 29569504
[TBL] [Abstract][Full Text] [Related]
15. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.
Kreuz W; Martinez-Saguer I; Aygören-Pürsün E; Rusicke E; Heller C; Klingebiel T
Transfusion; 2009 Sep; 49(9):1987-95. PubMed ID: 19497056
[TBL] [Abstract][Full Text] [Related]
16. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
[TBL] [Abstract][Full Text] [Related]
17. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial.
Riedl MA; Hurewitz DS; Levy R; Busse PJ; Fitts D; Kalfus I
Ann Allergy Asthma Immunol; 2012 Jan; 108(1):49-53. PubMed ID: 22192966
[TBL] [Abstract][Full Text] [Related]
18. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses.
Mendivil J; Malmenäs M; Haeussler K; Hunger M; Jain G; Devercelli G
Drugs R D; 2021 Mar; 21(1):113-121. PubMed ID: 33646565
[TBL] [Abstract][Full Text] [Related]
19. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.
Zanichelli A; Azin GM; Cristina F; Vacchini R; Caballero T
Orphanet J Rare Dis; 2018 Apr; 13(1):51. PubMed ID: 29631595
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.
Reshef A; Grivcheva-Panovska V; Kessel A; Kivity S; Klimaszewska-Rembiasz M; Moldovan D; Farkas H; Gutova V; Fritz S; Relan A; Giannetti B; Magerl M
Pediatr Allergy Immunol; 2019 Aug; 30(5):562-568. PubMed ID: 30993784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
